title: Dinutuximab approved for high-risk neuroblastoma.
abstract: The FDA approved the use of dinutuximab, in combination with three other agents, for high-risk neuroblastoma, offering patients the first major new treatment in more than a decade.
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D009447:Neuroblastoma / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C112746:dinutuximab